Please use this identifier to cite or link to this item: https://doi.org/10.1038/onc.2017.334
DC FieldValue
dc.titleOncogenic RAS-induced CK1? drives nuclear FOXO proteolysis
dc.contributor.authorZhang, F
dc.contributor.authorVirshup, D.M
dc.contributor.authorCheong, J.K
dc.date.accessioned2020-09-09T04:12:12Z
dc.date.available2020-09-09T04:12:12Z
dc.date.issued2018
dc.identifier.citationZhang, F, Virshup, D.M, Cheong, J.K (2018). Oncogenic RAS-induced CK1? drives nuclear FOXO proteolysis. Oncogene 37 (3) : 363-376. ScholarBank@NUS Repository. https://doi.org/10.1038/onc.2017.334
dc.identifier.issn0950-9232
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/175130
dc.description.abstractEvasion of forkhead box O (FOXO) family of longevity-related transcription factors-mediated growth suppression is necessary to promote cancer development. Since somatic alterations or mutations and transcriptional dysregulation of the FOXO genes are infrequent in human cancers, it remains unclear how these tumour suppressors are eliminated from cancer cells. The protein stability of FOXO3A is regulated by Casein Kinase 1 alpha (CK1?) in an oncogenic RAS-specific manner, but whether this mode of regulation extends to related FOXO family members is unknown. Here we report that CK1? similarly destabilizes FOXO4 in RAS-mutant cells by phosphorylation at serines 265/268. The CK1?-dependent phosphoregulation of FOXO4 is primed, in part, by the PI3K/AKT effector axis of oncogenic RAS signalling. In addition, mutant RAS coordinately elevates proteasome subunit expression and proteolytic activity to eradicate nuclear FOXO4 proteins from RAS-mutant cancer cells. Importantly, dual inhibition of CK1? and the proteasome synergistically inhibited the growth of multiple RAS-mutant human cancer cell lines of diverse tissue origin by blockade of nuclear FOXO4 degradation and induction of caspase-dependent apoptosis. Our findings challenge the current paradigm that nuclear export regulates the proteolysis of FOXO3A/4 tumour suppressors in the context of cancer and illustrates how oncogenic RAS-mediated degradation of FOXOs, via post-translational mechanisms, blocks these important tumour suppressors. © 2018 The Author(s).
dc.publisherNature Publishing Group
dc.sourceUnpaywall 20200831
dc.subjectcasein kinase Ialpha
dc.subjectcaspase
dc.subjectnuclear protein
dc.subjectphosphatidylinositol 3 kinase
dc.subjectproteasome
dc.subjectprotein FOXO4
dc.subjectprotein kinase B
dc.subjectRas protein
dc.subjectserine
dc.subjecttranscription factor FKHRL1
dc.subjecttranscription factor FOXO
dc.subjecttumor suppressor protein
dc.subjectunclassified drug
dc.subject4-(4-(2,3-dihydrobenzo(1,4)dioxin-6-yl)-5-pyridin-2-yl-1H-imidazol-2-yl)benzamide
dc.subjectbenzamide derivative
dc.subjectcasein kinase Ialpha
dc.subjectFOXO3 protein, human
dc.subjectFOXO4 protein, human
dc.subjectimidazole derivative
dc.subjectKRAS protein, human
dc.subjectproteasome
dc.subjectproteasome inhibitor
dc.subjectprotein p21
dc.subjectserine
dc.subjectsmall interfering RNA
dc.subjecttranscription factor
dc.subjecttranscription factor FKHRL1
dc.subjectapoptosis
dc.subjectArticle
dc.subjectcancer cell line
dc.subjectcancer growth
dc.subjectcell mutant
dc.subjectcolon cancer
dc.subjecthuman
dc.subjecthuman cell
dc.subjectnuclear export
dc.subjectpriority journal
dc.subjectprotein degradation
dc.subjectprotein expression
dc.subjectprotein induction
dc.subjectprotein phosphorylation
dc.subjectprotein processing
dc.subjectregulatory mechanism
dc.subjectsignal transduction
dc.subjectantagonists and inhibitors
dc.subjectcell cycle
dc.subjectcell nucleus
dc.subjectdrug effect
dc.subjectgenetics
dc.subjectmetabolism
dc.subjectmutation
dc.subjectneoplasm
dc.subjectpathology
dc.subjectphosphorylation
dc.subjectprotein degradation
dc.subjecttumor cell line
dc.subjectApoptosis
dc.subjectBenzamides
dc.subjectCasein Kinase Ialpha
dc.subjectCell Cycle
dc.subjectCell Line, Tumor
dc.subjectCell Nucleus
dc.subjectForkhead Box Protein O3
dc.subjectHumans
dc.subjectImidazoles
dc.subjectMutation
dc.subjectNeoplasms
dc.subjectPhosphorylation
dc.subjectProteasome Endopeptidase Complex
dc.subjectProteasome Inhibitors
dc.subjectProtein Processing, Post-Translational
dc.subjectProteolysis
dc.subjectProto-Oncogene Proteins p21(ras)
dc.subjectRNA, Small Interfering
dc.subjectSerine
dc.subjectSignal Transduction
dc.subjectTranscription Factors
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1038/onc.2017.334
dc.description.sourcetitleOncogene
dc.description.volume37
dc.description.issue3
dc.description.page363-376
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_onc_2017_334.pdf7.94 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.